… ProQR Announces First Quarter 2020 Operating and Financial Results Reported positive interim analysis findings … for severe genetic rare diseases, today reported its financial results for the first quarter ended March 31, 2020 …
… ProQR Announces Financial Results for the First Quarter of 2019 LEIDEN, … of severe genetic rare diseases, today reported its financial results for the first quarter ended March 31, 2019. …
… ProQR Announces Financial Results for the Second Quarter of 2019 … of severe genetic rare diseases, today reported its financial results for the second quarter ended June 30, 2019. …
Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data from Cohort 1 expected by year-end, and target engagemen
Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett SyndromeHosting fall Analyst and Investor Event (virtual), featuring detailed AX-0810 P
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief